Conference call and webcast to be held
Wednesday, October 30, 2024 at
12 p.m. ET/ 9
a.m. PT
LA JOLLA, Calif.,
Oct. 28,
2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica")
(Nasdaq: CALC), a clinical-stage biopharmaceutical company focused
on developing novel calcium release-activated calcium (CRAC)
channel inhibition therapies for acute and chronic inflammatory and
immunologic illnesses, today announced that it will host a call on
Wednesday, October 30, 2024 at
12 p.m. ET/ 9
a.m. PT to review the full data set and win ratio analysis
from the Company's Phase 2b CARPO
trial of Auxora™ in acute pancreatitis (AP) with accompanying
systemic inflammatory response syndrome (SIRS). Prof. Robert Sutton, University
of Liverpool and Liverpool
University Hospitals NHS Foundation Trust and chair of the
Steering Committee for the CARPO trial, will deliver his plenary
presentation from the American College of Gastroenterology (ACG)
2024 Annual Scientific Meeting, entitled "A Randomized,
Double-Blind, Placebo Controlled Dose Ranging Study of Auxora in
Patients with AP and Accompanying SIRS - CARPO."
Conference Call and Webcast Details
Stockholders and
other interested parties may access the call by following the
instructions below. A live webcast of the event can also be
accessed in the "Upcoming Events" section of CalciMedica's IR
website at https://ir.calcimedica.com/. The archived webcast will
be available following the completion of the event.
Participant Webcast Link:
https://app.webinar.net/4EanW4A2PXk
Click on the webcast link and complete the
online registration form.
Upon registering, you will be connected to the
online webcast.
Participant Dial-in Numbers: 1-646-357-8785 (US) and
1-800-836-8184 (international)
If prompted by the operator, ask to join the
CalciMedica Phase 2b CARPO Full Data
Set & Win Ratio call.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic
diseases. CalciMedica's proprietary technology targets
the inhibition of CRAC channels to modulate the immune response and
protect against tissue cell injury, with the potential to provide
therapeutic benefits in life-threatening inflammatory and
immunologic diseases for which there are currently no approved
therapies. CalciMedica's lead product candidate Auxora™
has demonstrated positive and consistent clinical results in
multiple completed efficacy clinical
trials. CalciMedica has announced topline data for a
Phase 2b trial (called CARPO
– NCT04681066) in patients with AP with SIRS and completed a
Phase 2 trial (called CARDEA – NCT04345614) in patients with
COVID pneumonia. The Company is currently conducting a Phase 2
trial (called KOURAGE – NCT06374797) in patients with AKI with
associated AHRF and continuing to support the ongoing Phase 1/2
trial (called CRSPA – NCT04195347) in patients with
AIPT. CalciMedica was founded by scientists from Torrey
Pines Therapeutics and the Harvard CBR Institute for
Biomedical Research, and is headquartered in La Jolla,
CA. For more information, please
visit www.calcimedica.com.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-host-a-call-to-review-full-data-set-including-a-win-ratio-analysis-from-phase-2b-carpo-trial-of-auxora-in-acute-pancreatitis-ap-302287906.html
SOURCE CalciMedica, Inc.